Wednesday, 8 April 2026
  
Login

Australia's most trusted
source of pharma news

Wednesday, 08 April 2026
News

First oral SERD registered

Posted 7 April 2026 AM

A Menarini’s Orserdu has finally been registered on the ARTG, marking the first oral SERD in Australia with the company actively seeking reimbursement for breast cancer patients.

The TGA previously told Pharma in Focus that it had approved Orserdu, however it was yet to appear on the ARTG as the company had decided not to supply the medicine in Australia for the time being.

To see the whole article, please login

Popular

Global pharma inks Arrotex deal
Seven novel drugs hit the PBS
Aussie pharma exec wins CEO job
And again... MA fills media role
Latest Jobs
Pharma in Focus  Jobs

Marketing & Communications (2)

Sales & Customer Relations (14)

Clinical & Medical, R&D (6)

Regulatory, Pharmacovigilance & QA (4)

Other (8)

MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.


Subscribe
 
© 2003 - 2026 Lush Media | Privacy Statement | Subscribe to Pharma in Focus
home